Back to search

Article

Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma multiforme: results from a nationwide real-world evidence database

2024-01-30

Abstract excerpt

<h4>Background</h4> Aldehyde dehydrogenase-1A1 (ALDH1A1) is a primary metabolic enzyme impacting outcome of chemotherapy, including temozolomide, the standard-of-care (SOC) for glioblastoma multiforme (GBM). High expression of ALDH1A1 is associated with poor prognosis in multiple cancers. Proton pump inhibitors (PPIs) are often prescribed to manage corticosteroid-induced gastrointestinal toxicity but were recently...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d465f9bd-7828-5f4e-bdb1-3eab8313565b
DOI
10.1101/2024.01.28.24301899
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma multiforme: results from a nationwide real-world evidence databaseDOI 10.1101/2024.01.28.24301899
Integrative multi-omics combined with functional pharmacological profiling in patient-derived organoids identifies personalized therapeutic vulnerabilities of adult high-grade gliomasSemantic proximity
A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools.Semantic proximity
Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.Semantic proximity
Old Does Not Necessarily Mean Worse: Standard Stupp Regimen for Elderly Patients (≥ 70 years) with Newly Diagnosed GlioblastomaSemantic proximity
MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesSemantic proximity
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.Semantic proximity
Four decades of glioblastoma targeted therapy: a bibliometric and pharmacological perspective on translational failure and future directionsSemantic proximity
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.Semantic proximity
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.Semantic proximity
Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trialSemantic proximity
PINK1 Expression as a Prognostic Biomarker in Glioblastoma Multiforme: An Observational Multicenter StudySemantic proximity
Hydralazine as a Repurposed Epigenetic and Metabolic Modulator in Glioblastoma: Promise, Pitfalls, and Future DirectionsSemantic proximity
Select a neighboring publication to make it the new centre.